Source: Optimi Health Corp.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Optimi (OPTI) has launched Blue Serenity, Canada’s first natural therapeutic psilocybin product
  • Blue Serenity is standardized to contain a total of 25 milligrams of natural psilocybin in the form of EU-GMP biomass grown as Panaeolus cyanescens mushrooms cultivated at Optimi Labs Inc. in Princeton, British Columbia
  • Blue Serenity will be available upon request to all legal psilocybin patients whose access has been approved by Health Canada
  • Optimi Health Corp. (OPTI) is up 10.53 per cent, trading at C$0.42 per share at 9:20 am ET

Optimi (OPTI) has launched Blue Serenity, Canada’s first natural therapeutic psilocybin product.

Blue Serenity is standardized to contain a total of 25 milligrams of natural psilocybin in the form of EU-GMP biomass grown as Panaeolus cyanescens mushrooms cultivated at Optimi Labs Inc. in Princeton, British Columbia.

Blue Serenity was launched in collaboration with psilocybin patient advocate Thomas Hartle.

He said that the name “Blue Serenity” touches on the emotional and visual aspect of his psilocybin experience.

“Blue Serenity was born from an experience that took me from a state of extreme anxiety to a feeling of calm that I never knew existed.”

Optimi Health CEO Bill Ciprick called the launch of Blue Serenity a moment to pause and reflect on Hartle’s contributions to a world beyond psychedelics.

“Anyone who has entered the psychedelics space in the last two years will tell you that Thomas Hartle’s story of compassion and kindness inspired them in some way to want to make a difference,” said Ciprick. “We are tremendously excited to be partnering with Thomas to become the first Canadian company to launch a natural psilocybin product specifically to help patients seeking relief through the Special Access Program.” 

He added that proceeds from the sale of Blue Serenity will directly benefit psilocybin patients through Hartle’s new charity, a venture that will provide access to psilocybin therapy for underserved adults. 

Blue Serenity will be available upon request to all legal psilocybin patients whose access has been approved by Health Canada.

Optimi Health focuses on producing and supplying natural, EU-GMP grade psilocybin and functional mushrooms for the health and wellness markets.

Optimi Health Corp. (OPTI) is up 10.53 per cent, trading at C$0.42 per share at 9:20 am ET.


More From The Market Herald
Resverlogix Corp. - SVP of Clinical Development, Dr. Michael Sweeney.

" Resverlogix (TSX:RVX) focuses drug development on COVID-19

Clinical development of Resverlogix’s (RVX) candidate apabetalone will remain focused on preventing and treating post-COVID-19 conditions.
CULT Food Science - CEO, Lejjy Gafour.

" CULT Food Science (CSE:CULT) portfolio company De Novo Dairy receives venture funding

CULT (CULT) portfolio company De Novo Dairy has secured funding from UM6P Ventures.

" No pain, no blood: BETTER Type 2 diabetes testing is coming to market

Over the past two years, reporting on the Covid-19 pandemic has dominated media airwaves.
The Market Herald Video

" BioVaxys (CSE:BIOV) expands vaccines intellectual property portfolio

BioVaxys Technology Corp. (BIOV) has broadened patent coverage for its viral vaccine platform.